Hzf and hCAS/CSE1L: making the right choice in p53-mediated tumour suppression.
Ewings
Katherine E
KE
Tumour Cell Death Laboratory, Beatson Institute for Cancer Research, Cancer Research UK Beatson Laboratories, Garscube Estate, Switchback Rd, Glasgow, G61 1BD, UK.
Ryan
Kevin M
KM
D000818:Animals; D017209:Apoptosis / Q000235:genetics / Q000502:physiology; D029563:Cellular Apoptosis Susceptibility Protein / Q000235:genetics / Q000378:metabolism*; D004249:DNA Damage; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D008954:Models, Biological; D009369:Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D011485:Protein Binding; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism* / Q000502:physiology
D029563:Cellular Apoptosis Susceptibility Protein; D004268:DNA-Binding Proteins; D016159:Tumor Suppressor Protein p53